To quantify the extent and determinants of underutilization of angiotensin-converting enzyme (ACE) inhibitots for patients with congestive heart failure, especially with respect to physician specialty and clinical indication.
T he appropriate role of generalist and specialist physi cimls in the care of patients is controversial, 1 It is generally assumed that the sickest, most complicated patients, as well as patients with rare disorders, benefit most from specialty care. However. the majority of patients with chronic diseases such as heart failure, diabetes, or chronic obstructive pulmonary disease initially are not severely ill. and are therefore first seen by the generalist physician. The most cost-effective threshold for specialty referral and the optimal mbr of generalist and spe cialist care remain unknown,:
Congestive heart failure is an ideal model to study variation in physicians' practice patterns among patients with chronic disease. This syndrome is common and presently the domain of both generalist and specialist physicians. Advances in cardiac transplantation and hemody namically titrated therapy have made some of the sickest patients clear candidates for referral to cardiologists, 3 Recently, however, multicenter trials of angiotensin converting enzyme (ACE) inhibitors have modified the standard of treatment for a broad rmlge of patients with heart failure, 4 These medications have been found to decrease mortality in patients with chronic heart failure and ejection fractions of 0,35 or less. E' decrease progression to hospital admission or death in patients with ejection fractions of 0.35 or less who are asymptomatic/and decrease mortality in asymptomatic patients who have suffered myocardial infarctions and have ejection fractions of 0.40 or less, 7 The Agency for Health Care Policy and Research, the American College of Cardiology, and the American Heart Association all currently recommend the use of 523 JGIM ACE inhibitors for patients with heart failure and left ventricuiar ejection fractions of 0.35 or less in their respec tive clinical practice guidelines. ~.'~ A variety of studies originating from 1-m~domized controlled trials, 1~ single institutions, l~na localized geo graphic areas, 14 and the pharmaceutical indusb-y is suggest that physicians greatly underutilize ACE inhibitors, Given the prevalence of congestive heart failure, thou sands of patients would benefit if physicians prescribed these therapeutic agents appropriately, However. these studies were completed either before or shortly after the major multicenter trials demonstrating the benefit of ACE inhibitors were published, particularly among asymptomatic populations. Also, few investigators have attempted to determine physician and patient factors associated with underutilization, ls,15 mid whether underdosing occurs, is Therefore, we surveyed physicians about their knowl edge of ACE inhibitors to explore whether underutflization of these medications persists, We aimed to determine whether patterns of sel~reported use of ACE inhibitors vary by spe cialty type and other attitudinal, cognitive, and demographic attributes of the physicians, as well as by indication for the medication and the severity of the patient's illness.
METHODS

Study Population
Between October 1995 and May 1996. we mailed an 8-page survey to a national systematic sample of 500 family practitioners, 500 general internists, and 500 car diologists chosen from the American Medical Association Physician Masteffile. All physicians were office based and in clinical practice. Nonrespondents were sent two further mailings and a reminder letter.
Data Collection
We presented three written case simulations of patients who had reduced ejection fraction, all based on recent data from lm*ge randomized, controlled trials demonstrating the survival mid morbidity benefits of ACE inhibitors, Cases described were an asymptomatic patient. ~' a patient with chronic heart failure on digitalis and a diuretic, s and an asymptomatic patient who was post-myocardial infarction (see AppendLx A). 7 The physiologic and laboratory data used in each simulation were the mean values re ported for the patients of the corresponding clinical trial. After each case simulation, we asked the physicians about which medication or medications, if any, they would pre scribe at that time. as well as how much they perceived that these agents would alter survival or morbidity.
We also presented another simulation of a patient's initial presentation mid follow-up visit to the office with symptomatic heart failure and ejection fraction equal to 0.35. We asked what drug the physician would choose at each visit, assuming that a medication needed to be selected. For this particular case simulation, we credited physicians with choosing an ACE inhibitor if they pre scribed this medication at either the first or second oftice visit in the hypothetical scenario,
We also inquired about how the physician decides what the final dose of the ACE inhibitor should be, what is the lowest systolic blood pressure he or she is willing to tolerate, and at what serum creatinine and potassium lev els the doctor tends to avoid prescribing ACE inhibitors. We instructed the physicians to think about their own heart failure patients with left ventricular systolic dys function as they completed the questionnaire. We also asked each physician to estimate rates of cough, hyperkalemia, renal failure, and hypotension among patients taking ACE inhibitors, and to rate the utility of different sources of information regarding heart failure medications, We obtained demographic information from both the survey and the Masterffie. We also inquired about the num ber of patients with congestive heart failure that each physician treats. We assigned eligible physicians into the spe cialty group listed in the Masterfile to allow comparisons between respondents and nonrespondents. Agreement between sel~designated specialty and Masterfile specialty was 94%/br eli~ble physicim~s. Moreover, 75% of the Masterfile designated cardiologists stated that at least 90% of their patients had cardiac problems. In contrast, only 0.5% of the family practitioners and 4% of the general internists had this percentage of cardiac patients in their practices,
Statistical Methods
We compared characteristics of respondents and nonrespondents using the Cochran Mantel-Haenszel X: statistic stratified by specialty, For comparisons across specialty groups, we used X ~ tests for categorical vari ables, and analysis of variance for continuous variables. We used stepwise multivariable logistic regression to determine independent factors associated with the use of ACE inhibitors for each case simulation. In these analy ses. we automatically adjusted for the physician's gender, geographic region, and number of years since graduation from medical school, as well as the number of patients with congestive heart failm-e in each doctor's practice. All specialty dummy variables were also included. For the remain ing candidate variables, we used entry criterion p -<. 10 and stay criterion p -< .05, two-tailed,
RESULTS
Survey Response Rate
Of the 1,500 physicians in the original sample, 91 had incorrect addresses or had died. The remaining 1,409 physicians comprised 727 eligible physicians who re turned usable surveys: 97 physicians who returned surveys but were ineligible because they had either retired or no longer took care of patients (69), or were neither a car diologist, a faxizily practitioner, nor a general internist (28): and 585 physicians who did not return the survey and consequently had u n k n o w n eligibility, Thus. our crude response rate (usable surveys per a s s u m e d eligible patients) was 7 2 7 / 1 . 3 1 2 55%. We then calculated an adjusted response rate based on standard techniques. 1~ Among the 824 physicians returning questionnaires, 727 (88%) were el igible. Applying this same percentage to the 585 physicimls with u n k n o w n eligibility, we estimated that 516 were eligible. Thus, the adjusted response rate (usable surveys per estimated eligible patients) was 7 2 7 / 1 . 2 4 3 580/0, The r e m a i n i n g results are b a s e d on the u n a d j u s t e d denomin a t o r s of physicians.
Eligibility r a t e s for family practitioners, general internists, and cardiologists were 83%. 870/0. mid 93%. respectively. Response rates for these s a m e physicians were 51%, 58%. and 57%. a nonsignificmlt difference with p ,10 ( Table 1 ). C o m p a r e d with respondents, n o n r e s p o n d e n t s were less likely (t9 < .001) to be b o a r d certified. Within each individual case simulation, the choice of medications was similar across w a v e s 1-3 of the survey, supporting the reliability of the findings.
Utilization of Angiotensin-Converting Enzyme Inhibitors by Specialty
More t h a n 88% of the physicians in each specialty group u s e d ACE inhibitors for symptomatic patients with chronic heart failure who were already receiving digitalis and a diuretic. However, family practitioners and general intenfists chose ACE inhibitors less frequently (p -< .01) t h a n cardiologists for the other indications (Fig. 1 ). Respec tire rates of ACE inhibitors use for each simulated patient were new-onset, symptomatic (fmnily practitioners 72%. general internists 76%, cardiologists 86%): asymptomatic (family practitioners 68%, general internists 78%, cardiolo gists 93%): and asymptomatic, post-myocardial ini~arction (family practitioners 58%, general internists 70%, cardiolo gists 94%),
Factors Associated with Physicians' Use of Angiotensin-Converting Enzyme Inhibitors
In bivariate analyses, cardiologists were more likely to prescribe ACE inhibitors thin1 were family practitioners, with the odds ratio (OR) for the different case s i m u l a tions rmlging from 2,4 in the new-onset, symptomatic case to 11,0 for the asymptomatic, post-myocardial infarction patient (Table 2) . To a lesser extent, general internists were also more apt to use these medications t h a n fmidly practitioners, O t h e r factors associated with the u s e of ACE inhibitors in bivariate a n a l
o n g p a t i e n t s with h e a r t failure. Higher perceived rates of side effects from ACE inhibitors were associated with decreased use of these m e d i c a t i o n s in the s i m u l a t i o n of the patient with chronic h e a r t failure and r e d u c e d eJec tion fraction. The gender and region of the physician were not correlated with the use of ACE inhibitors.
In multivariable a n a l y s e s a d j u s t i n g for the physi ciml"s gender, geographic region, y e a r s since graduation. a n d n u m b e r of patients with h e a r t failure in the practice. specialty differences were still significant (Table 3) . Cardi ologists were more likely t h a n family practitioners to use ACE inhibitors with a n a d j u s t e d OR ranging from 2.1 in 
the new onset, symptomatic case to 10.0 for the vignette of the asymptomatic, post-myocardial infarction patient, General internists also used these medications more often than family practitioners in the asymptomatic case with an adjusted OR of 1.9,
Estimates of Rates of Side Effects from Angiotensin-Converting Enzyme Inhibitors
Estimated rates of renal failure and hypotension from ACE inhibitors were slightly higher (p < .01) among cardi ologists than generalist physicians, However, the metal differences were clinically insignificant, varying by two percentage points across specialties. When the multivari able models for use of ACE inhibitors were also adjusted for estimated rates of cough, hyperkalemia, renal failure, and hypotension, cardiologists still used this class of medications more frequently than family practitioners in all case simulations. General internists also utilized these medications more often thin1 family practitioners in the asymptomatic scenario. For the entire sample of physi clans, the mean estimated rates (+SEM) of side effects were cough. 17o/o (--0.6%): hyperkalemia. 70/0 (--0.3%): renal failure, 6% (• and hypotension, 11% (+0.4%).
Dosage of Angiotensin-Convefling Enzyme Inhibitors
Several differences in attitudes about dosage of ACE inhibitors were apparent among the specialties (Table 4) Cardiologists were more likely (p < .05) than family prac titioners or general internists to titrate these medications to a specific dose. a specific blood pressure, or to the point of side effects. Family practitioners used lack of symptoms or signs of heart failure as end points more frequently than cardiologists. In addition, the cardiologists were more likely to tolerate a systolic blood pressure of 90 mm Hg or less (43% vs 15% for the generalists, p < .001). More than 25%
of the physicians in each specialty tended to avoid prescribing ACE inhibitors when the serum creatinine level was 176.8 t.mol/L (2,0 mg/dL) or higher.
Utility of Sources of Information About Heart Failure Medications
When asked to rate the utility of different sources of information for choosing medications for patients with heart failure, the cardiologists found original research a~ ticles and review articles to be more helpful (/) -< .01) than did the generalist physicimls (Table 5 ), The i~anKly practitioners and general internists rated colleagues more highly than the cardiologists did,
DISCUSSION
All physicians in this study tended to prescribe ACE inhibitors to patients with symptomatic heart failure already receiving digitalis and a diuretic, but family practi tioners and general internists tended to underutilize these medications in other subsets of patients with reduced ejection fractions, including the asymptomatic patient, the asymptomatic patient who is post-myocardial infarction.
and the newly symptomatic patient with heart failure, Differences across specialties were most striking among asymptomatic and post-myocardial infarction patients. What could explain the differences in the use of ACE inhibitors across specialties, particularly among asymp tomatic patients? Even after adjusting for the number of patients with heart failure that each physiciml treats, the estimated relative risk reduction from using medications in each case simulation, mid the estimated rates of side effects from ACE inhibitors, cardiologists were still more likely to use these agents.
Nonetheless. we cmmot rule out a number of other potential causes, For example, different physicians may require different amounts of scientific evidence to modify their practice. Generalist physicians may be aware of the latest studies, but might be withholding Judgment pend ing more data. Or, differences between the types of pa tients with heart failure cared for by generalists mid cardiologists may explain part of the variation in the pattern of drug selection. Perhaps patients cared for by generalist physicians are less likely to afford ACE inhibitors. We suspect, however, that ineffective dissemination of information about the specific role of ACE inhibitors in patients with asymptomatic heart failure is probably also playing a role. 1~ Compared with cardiologists, generalist physicians found original research articles less helpful and their colleagues" advice more useful, Our data also suggest underdosing of ACE inhibitors, In the various clinical trials, the doses of the ACE inhibi tors were generally increased to a target dose whenever tolerated, Trials currently in progress are testing the efficacy of lower doses. 1_~ Until these results are reported, an evidence-based approach to medicine advocates using the Second, early specialty consultation might be encou> aged. Knowledge increases rapidly, and tends to be adopted first by specialists. Nonetheless, we cannot extrapolate from our data that continuing care from a specialist, es pecially among the least sick patients, will necessarily lead to better outcomes.
Third, coordinated multidisciplinary interventions and disease management programs for heart failure, of which medication guidelines are an integral part, could improve the appropriateness of drug selection and decrease hospital readmissions and costs. 3~,3~ These programs" effects on noncardiac outcomes also need to be analyzed, partic ularly as so many older patients have multiple comorbid conditions. 1 The best solution for one health care system may not be generalizable to other organizations. Therefore, it may be prudent to allow each health care delivery system to devise the specific manner in which the care of its pm tients with heart failure is coordinated among different health care providers. Because congestive heart failure is the most common cause of hospitalization in the Medi care population, 33 flexible practice arrangements with easy access to specialists may reduce costs as well as improve outcomes.
APPENDLK A
Case Descriptions
Patient I : Initial Presentation of Heart Failure
A 65-year-old man comes into your office complaining of several weeks of shortness of breath and fatigue. He has no chest pain or dizziness. He is afebrile, blood pressure is 130/80, heart rate is ree~lar with a rate of 80, and respiratory rate is 20. Physical examination is sia~lificant %r bibasflar rales and a third heart sound. Clinically, you diaa~lose him with congestive heart failure.
You prescribe him a low-salt diet but feel that he also needs to be started on medication. You send him home on one medication and a low-salt diet. You order an echoeardiogram, which reveals an ejection fraction of 35%. He returns to yore-e~lic in 2 weeks, He is improved, but sKll tzas some shortness of breath, Blood pressure is 125/78 and heart beat is re.~_llar with a rate of 76. On physical examination his rales have disappeared, but he has a perNstent third heart sound. 
Patient 2: Asymptomatic
You see a 59 year old man with ischemic heart disease and an ejection fi-aetion of 28%. His blood pressure is 125/78 mm H~ and his heart rate is 75. He is in normal sinus rhyttmz He is asymptomatb.-. He is takizl~ aspirin, but is on no cardiac medications for congestive heart failure.
